Skip to main content
. 2014 Jun 4;1(6):446–456. doi: 10.18632/oncoscience.49

Figure 2. Treatment with AICAR or A-769662 suppressed proliferation in PC3 and PC3M cells.

Figure 2

Cell proliferation assay of PC3 and PC3M cells following treatment with (A, B) AICAR (500 and 2000 μM) or (C, D) A-769662 (50-300 μM); panels A, C for serum free medium and panels B, D for serum-supplemented medium. (E) Proliferation assay of PC3 and PC3M cells following treatment with AICAR (2000 μM) and Compound C (10 μM) alone or in combination, in serum free medium. Data presented in panels A-E are the values for mean ± SD of cell viability respective to (DMSO) control from three independent experiments, each with three technical replicates. For A through E * indicates significant difference at P ≤ 0.001, # at P ≤ 0.005, ▲ at P ≤ 0.01 and ▼ at P ≤ 0.05 from respective control. (F) PC3 and PC3M cells were incubated with siRNA targeting AMPKα1 alone or with AICAR (2000 μM) prior to cell proliferation assays. Data are presented as mean ± SD of cell viability respective to non-targeting, NT siRNA control from two independent experiments, each with three technical replicates. (G) Whole cell lysates were prepared from PC3 and PC3M cells following incubation with siRNA targeting AMPKα; Values under Western blots represent level of each protein normalized to GAPDH. Western blots are representative of two independent experiments.